Suboptimal EHR Reporting of Clinical Measures in Patients with RA Receiving a Biologic or Targeted Synthetic DMARD

VBCR - December 2017, Vol 6, No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

This retrospective analysis of the Optum One electronic health record (EHR) databases from various Integrated Delivery Networks (IDNs) and large group practices across the United States was conducted to examine the EHR reporting rates of several clinical measures among patients with rheumatoid arthritis (RA) who received a biologic or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

Clinical measures assessed included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or tuberculosis (TB) test, and validated disease severity measures (Routine Assessment of Patient Index Data 3 [RAPID3], Disease Activity Score [DAS28], or Clinical Disease Activity Index [CDAI]). Data from a total of 27 IDNs and 28 non-IDNs were included in this analysis. Patients (n = 29,829) were aged ≥18 years, had RA diagnoses ≥7 days apart between June 30, 2008, and July 31, 2015, and received ≥1 biologic or tsDMARDs indicated for RA treatment during the study period. The EHR reporting rates were presented for these clinical measures at baseline and follow-up. The 2 study cohorts evaluated included patients who switched from a tumor necrosis factor inhibitor (TNFi) to receive biologic or tsDMARDs (n = 7838), and those who received them without switching from a TNFi (n = 21,991).

The patient demographics were significantly different across the different IDN and non-IDN data sets. During the 1-year baseline period before the index date, among patients with RA who switched from a TNFi or received a biologic or tsDMARD, the EHR reporting rate of a TB test was 18.8% and varied significantly across the 10 IDNs, from 9.1% to 44.6%. During the first year of follow-up after switching, postindex ESR and/or CRP EHR reporting rates were 49.0%, and varied across IDNs from 23.4% to 70.4%. During 1-year follow-up, only 6.5% of patients had EHR reporting of ≥1 disease severity measures (RAPID3, 5.8%; DAS28, 0.2%; CDAI, 0.6%), with significant variation across IDNs ranging from 0.0% to 25.2%.

The authors concluded that more consistent and complete EHR reporting is recommended to assist rheumatologists in decision-making in terms of assessing whether RA treatment targets are being achieved and making necessary modifications if needed.

Source: Chastek B, Chen C-I, Kimura T, et al. Availability of clinical measures for patients with rheumatoid arthritis in integrated delivery networks who receive a biologic or targeted synthetic disease-modifying antirheumatic drug: a real-world analysis of an electronic health records database. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 130.

Related Items
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
Leslie Wyatt
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Adalimumab Biosimilar Shown to Be Safe and Effective in Patients with RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Treatment with Methotrexate Alone Yields Similar Outcomes to Combination Therapy in Early RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Working in Cold Environment Increases Risk for RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology